Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.

Also called NCT06381947

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
University of Salerno (from the registry)
Registry
  • NCT NCT06381947
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06381947. Randomized; no masking; primary purpose prevention. Start 2024-05-01 (anticipated); primary completion 2025-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
Acronym
BESAFE
Condition
Dyslipidemias
Condition
Statin Adverse Reaction
Condition
Cardiovascular Diseases
Condition
Lipid Metabolism Disorders
Intervention (Drug)
Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe
Intervention (Drug)
Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
Lead sponsor
University of Salerno (class: other)

Record details

Record id
cardio:ct-nct06381947
Content hash
b29d4c70f0fe636b7020e4136e721f12059e6573f8950cba1383840f3c4eeb02